ALK and non-small cell lung carcinoma: ALK positive patients by FISH represents in our study a 7.1% of the total, which is concordant with publications of other investigators in this population of patients [7]–[9], [16] and being the first ALK prevalence report in a cohort of predominantly metastatic European NSCLC patients.